Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 223

1.

Cancer Susceptibility Mutations in Patients With Urothelial Malignancies.

Carlo MI, Ravichandran V, Srinavasan P, Bandlamudi C, Kemel Y, Ceyhan-Birsoy O, Mukherjee S, Mandelker D, Chaim J, Knezevic A, Rana S, Fnu Z, Breen K, Arnold AG, Khurram A, Tkachuk K, Cipolla CK, Regazzi A, Hakimi AA, Al-Ahmadie H, Dalbagni G, Cadoo KA, Walsh MF, Teo MY, Funt SA, Coleman JA, Bochner BH, Iyer G, Solit DB, Stadler ZK, Zhang L, Rosenberg JE, Taylor BS, Robson ME, Berger MF, Vijai J, Bajorin DF, Offit K.

J Clin Oncol. 2019 Dec 3:JCO1901395. doi: 10.1200/JCO.19.01395. [Epub ahead of print]

PMID:
31794323
2.

Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer.

Apolo AB, Milowsky MI, Kim L, Inman BA, Kamat AM, Steinberg G, Bagheri M, Krishnasamy VP, Marko J, Dinney CP, Bangs R, Sweis RF, Maher VE, Ibrahim A, Liu K, Werntz R, Cross F, Beaver JA, Singh H, Pazdur R, Blumenthal GM, Lerner SP, Bajorin DF, Rosenberg JE, Agrawal S.

JAMA Oncol. 2019 Oct 31:1-9. doi: 10.1001/jamaoncol.2019.4114. [Epub ahead of print]

PMID:
31670753
3.

Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors.

Funt SA, Patil S, Feldman DR, Motzer RJ, Bajorin DF, Sheinfeld J, Tickoo SK, Reuter VE, Bosl GJ.

J Clin Oncol. 2019 Sep 10;37(26):2329-2337. doi: 10.1200/JCO.18.01608. Epub 2019 Jun 24.

PMID:
31233353
4.

PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available Antibodies.

Reis H, Serrette R, Posada J, Lu V, Chen YB, Gopalan A, Fine SW, Tickoo SK, Sirintrapun SJ, Iyer G, Funt SA, Teo MY, Rosenberg JE, Bajorin DF, Dalbagni G, Bochner BH, Solit DB, Reuter VE, Al-Ahmadie HA.

Am J Surg Pathol. 2019 Jul;43(7):920-927. doi: 10.1097/PAS.0000000000001264.

PMID:
31135485
5.

A New Twist to an Old Tale: Immunotherapy in Non-muscle-invasive Bladder Cancer.

Funt SA, Pietzak EJ, Bajorin DF.

Eur Urol Oncol. 2018 Aug;1(3):199-201. doi: 10.1016/j.euo.2018.07.001. Epub 2018 Jul 24. No abstract available.

PMID:
31102621
6.

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of > 2 years of follow-up.

Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Nam K, Frenkl TL, Perini RF, de Wit R, Bajorin DF.

Ann Oncol. 2019 May 3. pii: mdz127. doi: 10.1093/annonc/mdz127. [Epub ahead of print]

7.

Propensity-matched analysis of patient-reported outcomes for neoadjuvant chemotherapy prior to radical cystectomy.

Feuerstein MA, Goldstein L, Reaves B, Sun A, Goltzman M, Morganstern BA, Shabsigh A, Bajorin DF, Rosenberg JE, Donat SM, Herr HW, Laudone VP, Atkinson TM, Li Y, Dalbagni G, Rapkin B, Bochner BH.

World J Urol. 2019 Nov;37(11):2401-2407. doi: 10.1007/s00345-019-02692-z. Epub 2019 Feb 23.

8.

Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D'Angelo SP, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT.

Nat Genet. 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8. Epub 2019 Jan 14.

PMID:
30643254
9.

A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor.

Leiserson MDM, Syrgkanis V, Gilson A, Dudik M, Gillett S, Chayes J, Borgs C, Bajorin DF, Rosenberg JE, Funt S, Snyder A, Mackey L.

PLoS One. 2018 Dec 31;13(12):e0208422. doi: 10.1371/journal.pone.0208422. eCollection 2018.

10.

Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.

Audenet F, Isharwal S, Cha EK, Donoghue MTA, Drill EN, Ostrovnaya I, Pietzak EJ, Sfakianos JP, Bagrodia A, Murugan P, Dalbagni G, Donahue TF, Rosenberg JE, Bajorin DF, Arcila ME, Hechtman JF, Berger MF, Taylor BS, Al-Ahmadie H, Iyer G, Bochner BH, Coleman JA, Solit DB.

Clin Cancer Res. 2019 Feb 1;25(3):967-976. doi: 10.1158/1078-0432.CCR-18-2039. Epub 2018 Oct 23.

PMID:
30352907
11.

Surgical Management of Patients with Advanced Germ Cell Tumors Following Salvage Chemotherapy: Memorial Sloan Kettering Cancer Center (MSKCC) Experience.

Miller MI, Feifer A, Feldman DR, Carver BS, Bosl GJ, Motzer RJ, Bajorin DF, Sheinfeld J.

Urology. 2019 Feb;124:174-178. doi: 10.1016/j.urology.2018.09.024. Epub 2018 Oct 6.

PMID:
30296502
12.

Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.

Pietzak EJ, Zabor EC, Bagrodia A, Armenia J, Hu W, Zehir A, Funt S, Audenet F, Barron D, Maamouri N, Li Q, Teo MY, Arcila ME, Berger MF, Schultz N, Dalbagni G, Herr HW, Bajorin DF, Rosenberg JE, Al-Ahmadie H, Bochner BH, Solit DB, Iyer G.

Eur Urol. 2019 Feb;75(2):231-239. doi: 10.1016/j.eururo.2018.09.002. Epub 2018 Oct 2.

PMID:
30290956
13.

Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma."

Teo MY, Bambury RM, Zabor EC, Jordan E, Al-Ahmadie H, Boyd ME, Bouvier N, Mullane SA, Cha EK, Roper N, Ostrovnaya I, Hyman DM, Bochner BH, Arcila ME, Solit DB, Berger MF, Bajorin DF, Bellmunt J, Iyer G, Rosenberg JE.

Urol Oncol. 2018 Jul;36(7):345-346. doi: 10.1016/j.urolonc.2018.05.011. Epub 2018 May 30.

PMID:
29859727
14.

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.

Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, Wolf J, Dittrich C, Keam B, Delord JP, Schellens JHM, Gravis G, Medioni J, Maroto P, Sriuranpong V, Charoentum C, Burris HA, Grünwald V, Petrylak D, Vaishampayan U, Gez E, De Giorgi U, Lee JL, Voortman J, Gupta S, Sharma S, Mortazavi A, Vaughn DJ, Isaacs R, Parker K, Chen X, Yu K, Porter D, Graus Porta D, Bajorin DF.

Cancer Discov. 2018 Jul;8(7):812-821. doi: 10.1158/2159-8290.CD-18-0229. Epub 2018 May 30.

15.

Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.

Iyer G, Balar AV, Milowsky MI, Bochner BH, Dalbagni G, Donat SM, Herr HW, Huang WC, Taneja SS, Woods M, Ostrovnaya I, Al-Ahmadie H, Arcila ME, Riches JC, Meier A, Bourque C, Shady M, Won H, Rose TL, Kim WY, Kania BE, Boyd ME, Cipolla CK, Regazzi AM, Delbeau D, McCoy AS, Vargas HA, Berger MF, Solit DB, Rosenberg JE, Bajorin DF.

J Clin Oncol. 2018 Jul 1;36(19):1949-1956. doi: 10.1200/JCO.2017.75.0158. Epub 2018 May 9.

16.

Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy.

Sonpavde G, Pond GR, Rosenberg JE, Choueiri TK, Bellmunt J, Regazzi AM, Mullane SA, Necchi A, Raggi D, Lee JL, Lee S, Simpson J, Derleth CL, Lin SW, Bajorin DF.

Clin Genitourin Cancer. 2018 Aug;16(4):e961-e967. doi: 10.1016/j.clgc.2018.03.016. Epub 2018 Apr 6.

17.

Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor.

Pietzak EJ, Assel M, Becerra MF, Tennenbaum D, Feldman DR, Bajorin DF, Motzer RJ, Bosl GJ, Carver BS, Sjoberg DD, Sheinfeld J.

Urology. 2018 Aug;118:114-118. doi: 10.1016/j.urology.2018.04.009. Epub 2018 Apr 25.

PMID:
29704586
18.

Global Cancer Transcriptome Quantifies Repeat Element Polarization between Immunotherapy Responsive and T Cell Suppressive Classes.

Solovyov A, Vabret N, Arora KS, Snyder A, Funt SA, Bajorin DF, Rosenberg JE, Bhardwaj N, Ting DT, Greenbaum BD.

Cell Rep. 2018 Apr 10;23(2):512-521. doi: 10.1016/j.celrep.2018.03.042.

19.

Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma.

Isharwal S, Huang H, Nanjangud G, Audenet F, Chen YB, Gopalan A, Fine SW, Tickoo SK, Lee BH, Iyer G, Chadalavada K, Rosenberg JE, Bajorin DF, Herr HW, Donat SM, Dalbagni G, Bochner BH, Solit DB, Reuter VE, Al-Ahmadie HA.

Hum Pathol. 2018 Jul;77:63-69. doi: 10.1016/j.humpath.2018.03.015. Epub 2018 Mar 27.

20.

Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer.

Vaughn DJ, Bellmunt J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Li H, Perini RF, Bajorin DF, de Wit R.

J Clin Oncol. 2018 Jun 1;36(16):1579-1587. doi: 10.1200/JCO.2017.76.9562. Epub 2018 Mar 28.

PMID:
29590008
21.

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.

Teo MY, Seier K, Ostrovnaya I, Regazzi AM, Kania BE, Moran MM, Cipolla CK, Bluth MJ, Chaim J, Al-Ahmadie H, Snyder A, Carlo MI, Solit DB, Berger MF, Funt S, Wolchok JD, Iyer G, Bajorin DF, Callahan MK, Rosenberg JE.

J Clin Oncol. 2018 Jun 10;36(17):1685-1694. doi: 10.1200/JCO.2017.75.7740. Epub 2018 Feb 28.

22.

Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer.

Harshman LC, Tripathi A, Kaag M, Efstathiou JA, Apolo AB, Hoffman-Censits JH, Stadler WM, Yu EY, Bochner BH, Skinner EC, Downs T, Kiltie AE, Bajorin DF, Guru K, Shipley WU, Steinberg GD, Hahn NM, Sridhar SS.

Clin Genitourin Cancer. 2018 Jun;16(3):213-218. doi: 10.1016/j.clgc.2017.11.004. Epub 2017 Dec 6.

23.

Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis.

Chang MT, Penson A, Desai NB, Socci ND, Shen R, Seshan VE, Kundra R, Abeshouse A, Viale A, Cha EK, Hao X, Reuter VE, Rudin CM, Bochner BH, Rosenberg JE, Bajorin DF, Schultz N, Berger MF, Iyer G, Solit DB, Al-Ahmadie HA, Taylor BS.

Clin Cancer Res. 2018 Apr 15;24(8):1965-1973. doi: 10.1158/1078-0432.CCR-17-2655. Epub 2017 Nov 27.

24.

Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.

Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, Pradhan N, Arnold A, Walsh MF, Li Y, Balakrishnan AR, Syed A, Prasad M, Nafa K, Carlo MI, Cadoo KA, Sheehan M, Fleischut MH, Salo-Mullen E, Trottier M, Lipkin SM, Lincoln A, Mukherjee S, Ravichandran V, Cambria R, Galle J, Abida W, Arcila ME, Benayed R, Shah R, Yu K, Bajorin DF, Coleman JA, Leach SD, Lowery MA, Garcia-Aguilar J, Kantoff PW, Sawyers CL, Dickler MN, Saltz L, Motzer RJ, O'Reilly EM, Scher HI, Baselga J, Klimstra DS, Solit DB, Hyman DM, Berger MF, Ladanyi M, Robson ME, Offit K.

JAMA. 2017 Sep 5;318(9):825-835. doi: 10.1001/jama.2017.11137. Erratum in: JAMA. 2018 Dec 11;320(22):2381.

25.

Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer.

Bagrodia A, Sukhu R, Winer AG, Levy E, Vacchio M, Lee B, Pietzak EJ, Donahue TF, Cha E, Iyer G, Sjoberg DD, Vickers AJ, Rosenberg JE, Bajorin DF, Dalbagni G, Bochner BH.

Clin Genitourin Cancer. 2017 Aug 10. pii: S1558-7673(17)30232-X. doi: 10.1016/j.clgc.2017.07.022. [Epub ahead of print]

26.

Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma.

Isharwal S, Audenet F, Drill E, Pietzak EJ, Iyer G, Ostrovnaya I, Cha E, Donahue T, Arcila M, Jayakumaran G, Berger MF, Rosenberg JE, Bajorin DF, Coleman J, Dalbagni G, Reuter VE, Bochner BH, Solit DB, Al-Ahmadie HA.

Eur Urol Focus. 2019 Mar;5(2):201-204. doi: 10.1016/j.euf.2017.07.004. Epub 2017 Aug 10.

PMID:
28802642
27.

Pembrolizumab for Advanced Urothelial Carcinoma.

Bellmunt J, Bajorin DF.

N Engl J Med. 2017 Jun 8;376(23):2304. doi: 10.1056/NEJMc1704612. No abstract available.

PMID:
28591526
28.

Transposon mutagenesis identifies chromatin modifiers cooperating with Ras in thyroid tumorigenesis and detects ATXN7 as a cancer gene.

Montero-Conde C, Leandro-Garcia LJ, Chen X, Oler G, Ruiz-Llorente S, Ryder M, Landa I, Sanchez-Vega F, La K, Ghossein RA, Bajorin DF, Knauf JA, Riordan JD, Dupuy AJ, Fagin JA.

Proc Natl Acad Sci U S A. 2017 Jun 20;114(25):E4951-E4960. doi: 10.1073/pnas.1702723114. Epub 2017 Jun 5.

29.

Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.

Pietzak EJ, Bagrodia A, Cha EK, Drill EN, Iyer G, Isharwal S, Ostrovnaya I, Baez P, Li Q, Berger MF, Zehir A, Schultz N, Rosenberg JE, Bajorin DF, Dalbagni G, Al-Ahmadie H, Solit DB, Bochner BH.

Eur Urol. 2017 Dec;72(6):952-959. doi: 10.1016/j.eururo.2017.05.032. Epub 2017 Jun 3.

30.

Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.

Snyder A, Nathanson T, Funt SA, Ahuja A, Buros Novik J, Hellmann MD, Chang E, Aksoy BA, Al-Ahmadie H, Yusko E, Vignali M, Benzeno S, Boyd M, Moran M, Iyer G, Robins HS, Mardis ER, Merghoub T, Hammerbacher J, Rosenberg JE, Bajorin DF.

PLoS Med. 2017 May 26;14(5):e1002309. doi: 10.1371/journal.pmed.1002309. eCollection 2017 May.

31.

Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma In Situ of the Bladder who failed Bacillus Calmette Guerin (NCT01259063).

Dalbagni G, Benfante N, Sjoberg DD, Bochner BH, Machele Donat S, Herr HW, Mc Coy AS, Fahrner AJ, Retinger C, Rosenberg JE, Bajorin DF.

Bladder Cancer. 2017 Apr 27;3(2):113-119. doi: 10.3233/BLC-170095.

32.

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators.

N Engl J Med. 2017 Mar 16;376(11):1015-1026. doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17.

33.

Evaluating the association of multiple single nucleotide polymorphisms with response to gemcitabine and platinum combination chemotherapy in urothelial carcinoma of the bladder
.

Alanee SR, Shah S, Zabor EC, Vijai J, Ostrovnaya I, Garcia-Grossman IR, Pendse DV, Littman J, Regazzi AM, Offit K, Bajorin DF.

Int J Clin Pharmacol Ther. 2017 Mar;55(3):203-209. doi: 10.5414/CP202856.

PMID:
28177276
34.

DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.

Teo MY, Bambury RM, Zabor EC, Jordan E, Al-Ahmadie H, Boyd ME, Bouvier N, Mullane SA, Cha EK, Roper N, Ostrovnaya I, Hyman DM, Bochner BH, Arcila ME, Solit DB, Berger MF, Bajorin DF, Bellmunt J, Iyer G, Rosenberg JE.

Clin Cancer Res. 2017 Jul 15;23(14):3610-3618. doi: 10.1158/1078-0432.CCR-16-2520. Epub 2017 Jan 30.

35.

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group.

Lancet. 2017 Jan 7;389(10064):67-76. doi: 10.1016/S0140-6736(16)32455-2. Epub 2016 Dec 8. Erratum in: Lancet. 2017 Aug 26;390(10097):848.

36.

Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors.

Mano R, Becerra MF, Carver BS, Bosl GJ, Motzer RJ, Bajorin DF, Feldman DR, Sheinfeld J.

J Urol. 2017 Feb;197(2):391-397. doi: 10.1016/j.juro.2016.09.113. Epub 2016 Oct 5.

37.

Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors.

Bagrodia A, Lee BH, Lee W, Cha EK, Sfakianos JP, Iyer G, Pietzak EJ, Gao SP, Zabor EC, Ostrovnaya I, Kaffenberger SD, Syed A, Arcila ME, Chaganti RS, Kundra R, Eng J, Hreiki J, Vacic V, Arora K, Oschwald DM, Berger MF, Bajorin DF, Bains MS, Schultz N, Reuter VE, Sheinfeld J, Bosl GJ, Al-Ahmadie HA, Solit DB, Feldman DR.

J Clin Oncol. 2016 Nov 20;34(33):4000-4007. doi: 10.1200/JCO.2016.68.7798. Epub 2016 Sep 30.

38.

Genomic characterization of response to chemoradiation in urothelial bladder cancer.

Desai NB, Scott SN, Zabor EC, Cha EK, Hreiki J, Sfakianos JP, Ramirez R, Bagrodia A, Rosenberg JE, Bajorin DF, Berger MF, Bochner BH, Zelefsky MJ, Kollmeier MA, Ostrovnaya I, Al-Ahmadie HA, Solit DB, Iyer G.

Cancer. 2016 Dec 1;122(23):3715-3723. doi: 10.1002/cncr.30219. Epub 2016 Aug 1.

39.

Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.

Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ.

Bladder Cancer. 2016 Apr 27;2(2):165-202.

40.

Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma.

Abida W, Milowsky MI, Ostrovnaya I, Gerst SR, Rosenberg JE, Voss MH, Apolo AB, Regazzi AM, McCoy AS, Boyd ME, Bajorin DF.

Bladder Cancer. 2016 Jan 7;2(1):111-117.

41.

Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors.

Feldman DR, Hu J, Dorff TB, Lim K, Patil S, Woo KM, Carousso M, Hughes A, Sheinfeld J, Bains M, Daneshmand S, Ketchens C, Bajorin DF, Bosl GJ, Quinn DI, Motzer RJ.

J Clin Oncol. 2016 Jul 20;34(21):2478-83. doi: 10.1200/JCO.2016.66.7899. Epub 2016 May 16.

42.

Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer.

O'Donnell PH, Alanee S, Stratton KL, Garcia-Grossman IR, Cao H, Ostrovnaya I, Plimack ER, Manschreck C, Ganshert C, Smith ND, Steinberg GD, Vijai J, Offit K, Stadler WM, Bajorin DF.

Clin Genitourin Cancer. 2016 Dec;14(6):511-517. doi: 10.1016/j.clgc.2016.03.006. Epub 2016 Mar 10.

43.

Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.

Al-Ahmadie HA, Iyer G, Lee BH, Scott SN, Mehra R, Bagrodia A, Jordan EJ, Gao SP, Ramirez R, Cha EK, Desai NB, Zabor EC, Ostrovnaya I, Gopalan A, Chen YB, Fine SW, Tickoo SK, Gandhi A, Hreiki J, Viale A, Arcila ME, Dalbagni G, Rosenberg JE, Bochner BH, Bajorin DF, Berger MF, Reuter VE, Taylor BS, Solit DB.

Nat Genet. 2016 Apr;48(4):356-8. doi: 10.1038/ng.3503. Epub 2016 Feb 22.

44.

Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma.

Bagrodia A, Cha EK, Sfakianos JP, Zabor EC, Bochner BH, Al-Ahmadie HA, Solit DB, Coleman JA, Iyer G, Scott SN, Shah R, Ostrovnaya I, Lee B, Desai NB, Ren Q, Rosenberg JE, Dalbagni G, Bajorin DF, Reuter VE, Berger MF; Collaborators.

J Urol. 2016 Jun;195(6):1684-1689. doi: 10.1016/j.juro.2016.01.006. Epub 2016 Jan 14.

45.

The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents.

Tully CM, Apolo AB, Zabor EC, Regazzi AM, Ostrovnaya I, Furberg HF, Rosenberg JE, Bajorin DF.

Cancer. 2016 Mar 1;122(5):712-21. doi: 10.1002/cncr.29801. Epub 2015 Nov 30.

46.

Barriers to a Career Focus in Cancer Prevention: A Report and Initial Recommendations From the American Society of Clinical Oncology Cancer Prevention Workforce Pipeline Work Group.

Fabian CJ, Meyskens FL Jr, Bajorin DF, George TJ Jr, Jeter JM, Khan S, Tyne CA, William WN Jr.

J Clin Oncol. 2016 Jan 10;34(2):186-93. doi: 10.1200/JCO.2015.63.5979. Epub 2015 Nov 2.

47.

Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma.

Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Choueiri TK, Necchi A, Di Lorenzo G, Bellmunt J.

J Urol. 2016 Feb;195(2):277-82. doi: 10.1016/j.juro.2015.07.111. Epub 2015 Aug 17.

48.

Genomic Characterization of Upper Tract Urothelial Carcinoma.

Sfakianos JP, Cha EK, Iyer G, Scott SN, Zabor EC, Shah RH, Ren Q, Bagrodia A, Kim PH, Hakimi AA, Ostrovnaya I, Ramirez R, Hanrahan AJ, Desai NB, Sun A, Pinciroli P, Rosenberg JE, Dalbagni G, Schultz N, Bajorin DF, Reuter VE, Berger MF, Bochner BH, Al-Ahmadie HA, Solit DB, Coleman JA.

Eur Urol. 2015 Dec;68(6):970-7. doi: 10.1016/j.eururo.2015.07.039. Epub 2015 Aug 14.

49.

Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors.

Feldman DR, Glezerman I, Patil S, Van Alstine L, Bajorin DF, Fischer P, Hughes A, Sheinfeld J, Bains M, Reich L, Woo K, Giralt S, Bosl GJ, Motzer RJ.

Clin Genitourin Cancer. 2015 Oct;13(5):453-60. doi: 10.1016/j.clgc.2015.05.003. Epub 2015 May 16.

50.

The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience.

Bambury RM, Benjamin DJ, Chaim JL, Zabor EC, Sullivan J, Garcia-Grossman IR, Regazzi AM, Ostrovnaya I, Apollo A, Xiao H, Voss MH, Iyer G, Bajorin DF, Rosenberg JE.

Oncologist. 2015 May;20(5):508-15. doi: 10.1634/theoncologist.2014-0354. Epub 2015 Apr 6.

Supplemental Content

Loading ...
Support Center